GlassScriptPhysician profile
Kathyrn E Steele
NPI 1114228400
$2,992.96
in general payments reported to CMS, 2019-2025
29 companies · $996 in 2025
The $996 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.46 · 2022: $732 · 2023: $566 · 2024: $657 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,100 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,099.60 |
| Education | $119.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $359.47 | 2024-2025 | Jemperli, Zejula |
| Pfizer INC. | $339.90 | 2022-2025 | |
| Eisai INC. | $317.32 | 2023-2025 | |
| Seagen INC. | $261.15 | 2022-2023 | Tivdak |
| Tempus Ai, INC | $244.43 | 2025 | Xt Cdx |
| Myriad Genetic Laboratories, INC. | $207.22 | 2023-2024 | Myrisk |
| Astrazeneca Pharmaceuticals LP | $174.20 | 2022-2025 | Lynparza |
| Lilly USA, LLC | $139.44 | 2022-2023 | |
| Caris Mpi, INC. | $121.11 | 2025 | Mi Cancer Seek |
| Abbvie INC. | $103.64 | 2024 | |
| Amgen INC. | $92.41 | 2022-2025 | Repatha |
| Pharmacosmos Therapeutics INC. | $77.39 | 2022 | |
| Sobi, INC | $75.13 | 2022 | |
| Exelixis INC. | $56.90 | 2022 | |
| Novartis Pharmaceuticals Corporation | $56.49 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $48.77 | 2022 | |
| Genmab U.S., INC. | $41.82 | 2025 | |
| Janssen Biotech, INC. | $33.62 | 2022 | |
| Daiichi Sankyo INC. | $29.44 | 2024 | Injectafer |
| Welch Allyn | $27.24 | 2021 | |
| Corcept Therapeutics | $26.44 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $25.73 | 2024 | Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $23.41 | 2022 | |
| Adc Therapeutics America, INC. | $21.71 | 2023 | |
| Foundation Medicine, INC. | $21.26 | 2023 | |
| Taiho Oncology, INC. | $19.59 | 2022 | |
| Celgene Corporation | $17.87 | 2022 | |
| Gilead Sciences, INC. | $15.22 | 2021 | |
| Pharmaessentia USA Corporation | $14.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathyrn Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.